The effect of gut microbiome on tolerance to morphine mediated antinociception in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and in vitro tissue study with no human data
PubMed 28211545 · doi:10.1038/srep42658
What was done
Mice were treated with chronic morphine alongside gut bacterial depletion induced via oral gavage of an antibiotic cocktail (ABX) or non-absorbable oral vancomycin. The investigators evaluated gut permeability, colonic mucosal integrity, colonic IL-1β expression, nociception using tail-immersion and acetic acid stretch assays, naloxone-precipitated withdrawal, and ex vivo dorsal root ganglion primary afferent neuronal excitability.
What was found
No numerical values or confidence intervals were provided in the abstract. Qualitatively, antibiotic-mediated bacterial depletion significantly reduced gut bacteria, prevented chronic morphine-induced increases in gut permeability, colonic mucosal destruction, and colonic IL-1β expression, and prevented antinociceptive tolerance in both behavioral assays. Non-absorbable oral vancomycin alone also reduced tolerance. ABX preserved morphine-induced hypoexcitability in isolated dorsal root ganglion neurons, but it did not alter susceptibility to naloxone-precipitated withdrawal.
Why it matters
These findings suggest that gut microbiota play a direct mechanistic role in the development of opioid antinociceptive tolerance and associated intestinal inflammation, pointing to the gut microbiome as a potential therapeutic target in chronic opioid management.
Limits
The study was conducted entirely in mice, meaning findings cannot be directly extrapolated to human clinical pain management. The abstract omits sample sizes, specific drug dosages, baseline values, and exact quantitative effect sizes.
Cited by
- supports In experimental animals, depleting the gut microbiome with antibiotics significantly reduces the required dose of narcotics for an effect, and reintroducing the microbiome restores high tolerance.